Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines

医学 阴茎癌 恶性肿瘤 粘膜黑色素瘤 四分位间距 队列 癌症 淋巴血管侵犯 阴茎 黑色素瘤 龟头 泌尿科 外科 皮肤病科 内科学 转移 癌症研究
作者
Ömer Onur Çakır,Edoardo Pozzi,Fabio Castiglione,Alex Freeman,Aiman Haider,Rowland Rees,Hussain M. Alnajjar,Clareann H. Bunker,Asıf Muneer
出处
期刊:Melanoma Research [Lippincott Williams & Wilkins]
卷期号:32 (1): 27-34 被引量:8
标识
DOI:10.1097/cmr.0000000000000788
摘要

Penile mucosal melanoma is an aggressive and rare genital malignancy. The aim of the present study was to review the management and outcomes of a homogenous cohort of patients with histologically confirmed penile mucosal melanoma, at a single specialist centre. A retrospective review of an institutional database identified patients with penile mucosal melanoma over a 10-year period. Patient demographics, histopathological characteristics, type of primary surgery, recurrence, presence of metastatic disease and molecular markers were evaluated. The management of the patients was initially based on the European Association of Urology (EAU) penile cancer guidelines which are primarily for squamous cell carcinoma with inputs from a melanoma multidisciplinary team. Twelve patients with penile mucosal melanoma were analysed. Median [interquartile range (IQR)] age was 69.5 (67.25−81) years. The overall median follow-up (IQR) was 69.5 (20−114) months, while median follow-up for cancer-specific survival (CSS) was 11.5 (8−37) months. Location of the primary tumour was glans penis ( n = 7), urethra ( n = 2) and inner prepuce ( n = 3). The CSS at 1, 2 and 5 years after primary surgery was 33%, 16.7% and 0%, respectively. The recurrence-free survival at 1, 3 and 5 months after the primary surgery was 90%, 67% and 56%, respectively. All patients with metastatic disease or with inguinal lymph node invasion at presentation, died within 25 months of the primary diagnosis. Management based on the modified EAU penile cancer guidelines still led to poor outcomes. We present a management diagram based on our experience.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李爱国应助嘻嘻采纳,获得10
1秒前
1秒前
1秒前
天天快乐应助Brave采纳,获得10
2秒前
豆豆完成签到 ,获得积分10
4秒前
4秒前
4秒前
CipherSage应助agony采纳,获得10
5秒前
科目三应助优美晓灵采纳,获得10
6秒前
博客语法完成签到 ,获得积分10
6秒前
ww不迷糊完成签到 ,获得积分10
6秒前
QQ完成签到 ,获得积分10
6秒前
babale完成签到,获得积分10
6秒前
李大嘴完成签到,获得积分10
7秒前
碧蓝丹烟发布了新的文献求助30
7秒前
卿霜发布了新的文献求助10
8秒前
爱米粒725完成签到 ,获得积分10
8秒前
Sunny发布了新的文献求助10
8秒前
不想做实验完成签到,获得积分10
9秒前
研友_pnxBe8完成签到,获得积分10
10秒前
伶俐的万天完成签到,获得积分10
12秒前
落寞飞烟完成签到,获得积分0
12秒前
Alien完成签到 ,获得积分10
13秒前
专注的芷完成签到 ,获得积分10
13秒前
聪明的迎夏完成签到 ,获得积分10
13秒前
张凡完成签到 ,获得积分10
16秒前
17秒前
慕青应助廿二采纳,获得10
17秒前
njxray完成签到,获得积分10
18秒前
优美晓灵完成签到,获得积分10
18秒前
19秒前
大气钥匙完成签到,获得积分10
19秒前
22秒前
22秒前
希望天下0贩的0应助lx采纳,获得10
22秒前
xue发布了新的文献求助10
23秒前
24秒前
Jasper应助科研通管家采纳,获得10
24秒前
24秒前
Nole应助科研通管家采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Reducing Compassion Fatigue, Secondary Traumatic Stress and Burnout 600
China Pluperfect I: Epistemology of Past and Outside in Chinese Art 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Mammalian Synthetic Biology 500
Auslegungsgeschichte 500
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7638903
求助须知:如何正确求助?哪些是违规求助? 9212111
关于积分的说明 19761166
捐赠科研通 7205811
什么是DOI,文献DOI怎么找? 3275906
关于科研通互助平台的介绍 2437495
邀请新用户注册赠送积分活动 2273206